Navigation Links
Sigma-Aldrich (NASDAQ:SIAL) Announces it Has Filed Its December 31, 2008 Form 10-K
Date:2/27/2009

ST. LOUIS, Feb. 27 /PRNewswire-FirstCall/ -- A copy of the Company's December 31, 2008 Form 10-K, as filed with the Securities & Exchange Commission, may be obtained without charge at our website address, www.sigma-aldrich.com, or upon writing to the Secretary, Sigma-Aldrich Corporation, P. O. Box 14508, St. Louis, Missouri 63178.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and as key components in pharmaceutical, diagnostic and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 37 countries and has 7,900 employees providing excellent service worldwide. We are committed to accelerating our Customers' success through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award winning web site at www.sigma-aldrich.com.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
2. Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries
3. Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity
4. Sigma-Aldrich Corporations 4th Quarter 2008 Earnings Conference Call
5. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
6. Sigma-Aldrich Acquires Seppro(R) Depletion Technology From GenWay Biotech
7. Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes
8. Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
9. Sigma-Aldrich to Present at the 19th Annual Citi Chemicals Conference Tuesday, December 2, 2008
10. Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
11. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... , NATICK, Mass., Sept. 14 Boston ... that it has entered into a co-marketing agreement with ... testing solutions for urinary incontinence. Bladder Health Network ... supplies and results analysis, helping to ensure that physicians ...
... 14 Health Robotics today reported,that Dr M Group has ... of its I.V. Compounding Centers in Malaysia,Singapore, Indonesia, Vietnam, and ... on 2 companies in the field of I.V.,Robotics, the doubts ... announced multi-year delays in bringing their robot to first,hospital,s use], ...
... , , , ... announced that the results of a comprehensive review of safety data from ... Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, ... risk-benefit profile of pirfenidone in IPF patients, a comprehensive review of safety ...
Cached Biology Technology:Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 2Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 2Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 3Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 5Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 6Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 7Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 8
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... The microscopic phytoplankton Aureococcus anophagefferens , which causes ... to be a fierce competitor. In the first ... found that Aureococcus , unique gene complement allows ... human-modified ecosystems, which could help explain the global increases ...
... pathways that are mutated in many forms of cancer, ... disease including hypertrophic cardiomyopathy (HCM), a thickening of ... sudden death in children and young adults , have ... in the lab. In two separate but ...
... group of chemical compounds used by a species of ... promising antimalarial properties for humans. The compounds are part ... to battle enemies and that may provide a ... novel analytical process, researchers at the Georgia Institute of ...
Cached Biology News:First harmful algal bloom species genome sequenced 2First harmful algal bloom species genome sequenced 3Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4
pH-insensitive fluorescence (pH 2-12)...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Biology Products: